Leerink Partnrs Comments on Jazz Pharmaceuticals plc’s FY2024 Earnings (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report) – Equities research analysts at Leerink Partnrs upped their FY2024 earnings per share (EPS) estimates for Jazz Pharmaceuticals in a report released on Monday, January 29th. Leerink Partnrs analyst M. Goodman now forecasts that the specialty pharmaceutical company will post earnings of $17.41 per share for the year, up from their prior forecast of $17.34. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $15.35 per share. Leerink Partnrs also issued estimates for Jazz Pharmaceuticals’ FY2025 earnings at $19.43 EPS, FY2026 earnings at $22.01 EPS and FY2027 earnings at $19.86 EPS.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Free Report) last posted its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported $4.22 EPS for the quarter, beating the consensus estimate of $4.21 by $0.01. Jazz Pharmaceuticals had a return on equity of 22.23% and a net margin of 2.11%. The company had revenue of $972.14 million for the quarter, compared to the consensus estimate of $969.47 million.

Other equities analysts also recently issued research reports about the company. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Truist Financial reiterated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, December 4th. UBS Group cut Jazz Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $170.00 to $135.00 in a research note on Monday, November 27th. Barclays cut their target price on Jazz Pharmaceuticals from $240.00 to $235.00 and set an “overweight” rating for the company in a research note on Monday. Finally, Royal Bank of Canada cut their target price on Jazz Pharmaceuticals from $200.00 to $191.00 and set an “outperform” rating for the company in a research note on Thursday, November 9th. Two equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $195.90.

Read Our Latest Report on Jazz Pharmaceuticals

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $123.68 on Wednesday. Jazz Pharmaceuticals has a 12 month low of $111.25 and a 12 month high of $158.42. The stock’s 50 day moving average is $121.39 and its 200-day moving average is $128.14. The company has a current ratio of 2.06, a quick ratio of 1.67 and a debt-to-equity ratio of 1.46. The company has a market capitalization of $7.79 billion, a price-to-earnings ratio of 140.55, a PEG ratio of 0.96 and a beta of 0.61.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Mark Douglas Smith sold 417 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $119.27, for a total value of $49,735.59. Following the completion of the sale, the director now directly owns 6,888 shares in the company, valued at $821,531.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 4.40% of the stock is currently owned by company insiders.

Institutional Trading of Jazz Pharmaceuticals

A number of large investors have recently bought and sold shares of JAZZ. Massmutual Trust Co. FSB ADV grew its holdings in Jazz Pharmaceuticals by 65.6% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 202 shares of the specialty pharmaceutical company’s stock worth $26,000 after acquiring an additional 80 shares during the period. ST Germain D J Co. Inc. acquired a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at about $40,000. V Square Quantitative Management LLC acquired a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at about $44,000. Covestor Ltd grew its stake in shares of Jazz Pharmaceuticals by 676.5% in the 3rd quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company’s stock valued at $51,000 after buying an additional 345 shares during the period. Finally, Spire Wealth Management grew its stake in shares of Jazz Pharmaceuticals by 128.6% in the 3rd quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 238 shares during the period. 88.15% of the stock is currently owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

(Get Free Report)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors.

Recommended Stories

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.